In a clinical trial involving gliomas with the BRAF-V600E mutation, the BRAF inhibitor dabrafenib (NCT01677741) demonstrated significant clinical activity and was well tolerated in patients with this mutation. The gene discussed is BRAF; the disease is glioma.